Page last updated: 2024-10-15

iodohydroxybenzylpindolol

Description

iodohydroxybenzylpindolol: RN given refers to unlabeled cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156614111
MeSH IDM0058512

Synonyms (5)

Synonym
58946-16-0
4-(2-((2-hydroxy-3-(1h-indol-4-yloxy)propyl)amino)-2-methylpropyl)iodophenol
i-hyp
iodohydroxybenzylpindolol
ihyp

Research Excerpts

Overview

I-iodohydroxybenzylpindolol (IHYP) is a beta-adrenergic antagonist used as a ligand for the characterization of beta- adrenergic receptors in various cell preparations.

ExcerptReference
"125I-iodohydroxybenzylpindolol (IHYP) is a beta-adrenergic antagonist used as a ligand for the characterization of beta-adrenergic receptors in various cell preparations. "( Beta-adrenergic receptors of human polymorphonuclear leukocytes.
Ellis, EF; Lee, TP; Szefler, S, 1981
)

Dosage Studied

ExcerptReference
" The dose-response curve for propranolol inhibition of 125I-hydroxybenzylpindolol binding duplicated that reported for its physiologic action."( Beta receptor occupancy. Assessment in the intact animal.
Homcy, CJ; Kopiwoda, S; Strauss, HW, 1980
)
" Unexpected differences, not previously reportd, were found in the shapes of the cAMP accumulation dose-response curves of norepinephrine and isoproterenol."( Neonatal rat pinealocytes: typical and atypical characteristics of [125I]iodohydroxybenzylpindolol binding and adenosine 3',5'-monophosphate accumulation.
Auerbach, DA; Aurbach, GD; Klein, DC; Woodard, C, 1981
)
" The dose-response curves for isoprenaline competition in binding of [125I]iodohydroxybenzylpindolol by dividing cells showed that the EC50 (effective concentration for half maximum activity) value for isoprenaline was higher in the presence of p[NH]ppG."( Characteristics of the beta-adrenergic adenylate cyclase system of developing rabbit bone-marrow erythroblasts.
Arnstein, HR; Setchenska, MS, 1983
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (97)

TimeframeStudies, This Drug (%)All Drugs %
pre-199097 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.00%)5.53%
Reviews4 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other95 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]